home / stock / aneb / aneb news

ANEB News and Press, Anebulo Pharmaceuticals Inc. From 07/14/22

Stock Information
Company Name: Anebulo Pharmaceuticals Inc.
Stock Symbol: ANEB
Market: NASDAQ
Website: anebulo.com
Menu
ANEB ANEB Quote ANEB Short ANEB News ANEB Articles ANEB Message Board
Get ANEB Alerts

News, Short Squeeze, Breakout and More Instantly...
ANEB - Biomerica, Clene top healthcare gainers; ContraFect, Novavax lead losers' pack

Gainers: Biomerica ( BMRA ) +23% . Clene ( CLNN ) +22% . Gossamer Bio ( GOSS ) +11% . Revelation Biosciences ( REVB ) +10% . Nutriband ( NTRB ) +7% . Losers: ContraFect ( CFRX ) -81% . Novavax ( NVAX ) -1...
ANEB - Anebulo's drug ANEB-001 helps reduce cannabis high in phase 2 study

Anebulo Pharmaceuticals ( NASDAQ: ANEB ) said a phase 2 trial of oral drug ANEB-001 met the main goal of reducing cannabinoid intoxication. The company reported data from part A of an ongoing phase 2 trial, conducted in the Netherlands, of ANEB-001 against plac...

ANEB - Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Study Met Primary Endpoint VAS Feeling High (p < 0.0001) Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms Conference Call 8:30am Eastern Time Today Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage bio...

ANEB - Anebulo, Tenon top healthcare gainers; BioSig, Rigel lead losers' pack

Gainers: Anebulo Pharmaceuticals (ANEB) +32%. Tenon Medical (TNON) +19%. PolarityTE (PTE) +14%. TRACON Pharmaceuticals (TCON) +14%. Bausch Health (BHC) +13%. Losers: BioSig Technologies (BSGM) -26%. Rigel Pharmaceuticals (RIGL) -8%. Valneva (VALN) ...
ANEB - Anebulo Pharma to announce data from phase 2 trial for acute cannabinoid intoxication on July 5

Anebulo Pharma (NASDAQ:ANEB) said on Thursday that it expects to release topline data from one part of its ongoing Phase 2 study of ANEB-001 to potentially treat acute cannabinoid intoxication (ACI) on July 5. The company said the results of the study, which was conducted in sixty health...

ANEB - Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), anticipates relea...

ANEB - IPI, VRM and TWI among mid-day movers

Gainers: Fujian Blue Hat Interactive Entertainment Technology (BHAT) +323%. F-star Therapeutics (FSTX) +59%. Rain Therapeutics (RAIN) +43%. The9 Limited (NCTY) +36%. Vroom (VRM) +33%. MSP Recovery (MSPR) +23%. uniQure (QURE) +22%. Azure Power Global (AZRE) +22%. Valneva (VALN) +21%. Anebulo P...
ANEB - Anebulo Pharmaceuticals appoints Kenneth Cundy as chief scientific officer

Anebulo Pharmaceuticals (NASDAQ:ANEB) on Tuesday said it had appointed Kenneth Cundy as chief scientific officer. Cundy joins Anebulo from biotech company CohBar (CWBR). He had previously held various positions at Gilead Sciences (GILD). Cundy will lead ANEB’s research and develop...

ANEB - Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced t...

ANEB - Anebulo Pharmaceuticals GAAP EPS of -$0.08 misses by $0.03

Anebulo Pharmaceuticals press release (NASDAQ:ANEB): Q3 GAAP EPS of -$0.08 misses by $0.03. Cash and cash equivalents were $16.5 million as of March 31, 2022. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.08 misses by $0.03

Previous 10 Next 10